keyword
MENU ▼
Read by QxMD icon Read
search

asparaginase hypersensitivity

keyword
https://www.readbyqxmd.com/read/27908241/molecular-cloning-biochemical-characterization-and-antitumor-properties-of-a-novel-l-asparaginase-from-synechococcus-elongatus-pcc6803
#1
R Kebeish, A El-Sayed, H Fahmy, A Abdel-Ghany
L-asparaginase (EC 3.5.1.1), which catalyzes the deamidation of L-asparagine to L-aspartic acid and ammonia, has been widely used as a key therapeutic tool in the treatment of tumors. The current commercially available L-asparaginases, produced from bacteria, have signs of toxicity and hypersensitivity reactions during the course of tumor therapy. Therefore, searching for L-asparaginases with unique biochemical properties and fewer adverse effects was the objective of this work. In this study, cyanobacterial strain Synechococcus elongatus PCC6803 was found as a novel source of L-asparaginase...
October 2016: Biochemistry. Biokhimii︠a︡
https://www.readbyqxmd.com/read/27779086/genetic-predictors-of-drug-hypersensitivity
#2
José A Cornejo-García, Abderrahim Oussalah, Miguel Blanca, Rosa-María Guéant-Rodríguez, Cristobalina Mayorga, Julie Waton, Annick Barbaud, Francesco Gaeta, Antonino Romano, Jean-Louis Guéant
Our knowledge of genetic predisposing factors of drug hypersensitivity reactions (DHRs) is still scarce. The analysis of the genetic basis of these reactions may contribute to dissect the underlying mechanisms. We will outline current knowledge of the genetic predictors of most common DHRs, including reactions to betalactam antibiotics (BLs), nonsteroidal anti-inflammatory drugs (NSAIDs) and biological agents. The predictors of DHRs to BLs are mostly linked to IgE-class switching, IgE pathway and atopy (IL4R, NOD2, LGALS3) in replicated candidate gene studies, and to antigen presentation (HLA-DRA) in the single replicated GWAS performed so far...
September 27, 2016: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/27754445/l-asparaginase-isolated-from-phaseolus-vulgaris-seeds-exhibited-potent-anti-acute-lymphoblastic-leukemia-effects-in-vitro-and-low-immunogenic-properties-in-vivo
#3
Saleh A Mohamed, Mohamed F Elshal, Taha A Kumosani, Alia M Aldahlawi, Tasneem A Basbrain, Fauziah A Alshehri, Hani Choudhry
Escherichia coli-derived L-asparaginases have been used in the treatment of acute lymphoblastic leukemia (ALL), however, clinical hypersensitivity reactions and silent inactivation due to antibodies against E. coli-asparaginase, lead to inactivation of these preparations in most cases.Therefore, this study was aimed to investigate the cytotoxicity and antitumor effects ofa novel L-asparaginaseenzyme, isolated from Phaseolus vulgaris seeds (P-Asp) on the ALL cell line (Jurkat). The immunogenicity of the enzyme was also evaluated in-vivo and results were compared to commercially available enzymes of microbial sources...
October 14, 2016: International Journal of Environmental Research and Public Health
https://www.readbyqxmd.com/read/27631159/the-use-of-erwinia-asparaginase-for-adult-patients-with-acute-lymphoblastic-leukemia-after-pegaspargase-intolerance
#4
Troy Z Horvat, Joshua J Pecoraro, Ryan J Daley, Larry W Buie, Amber C King, Raajit K Rampal, Martin S Tallman, Jae H Park, Dan Douer
Asparaginase administration has become a crucial component of front-line pediatric and pediatric-insipired multi-agent regimens for the treatment of acute lymphoblastic leukemia (ALL). The aim of this retrospective study was to assess the safety and feasibility of switching to Erwinia asparaginase after pegaspargase intolerance in adult ALL patients treated at Memorial Sloan Kettering Cancer Center. Our analysis included 10 patients, with a median age of 39 years (range 20-72), male predominance (90%), and a typical B-cell to T-cell ratio (70:30%) for ALL...
August 26, 2016: Leukemia Research
https://www.readbyqxmd.com/read/27578304/comparison-of-hypersensitivity-rates-to-intravenous-and-intramuscular-peg-asparaginase-in-children-with-acute-lymphoblastic-leukemia-a-meta-analysis-and-systematic-review
#5
Haroon Hasan, Omar Mohammad Shaikh, Shahrad Rod Rassekh, A Fuchsia Howard, Karen Goddard
BACKGROUND: Pegylated-asparaginase (PEG-ASP) is a critical treatment for pediatric acute lymphoblastic leukemia (ALL) and has traditionally been delivered via intramuscular (IM) injection. In an attempt to reduce pain and anxiety, PEG-ASP has increasingly been delivered via intravenous (IV) administration. The study objective was to perform a meta-analysis and systematic review to compare and generate pooled hypersensitivity rates for IM and IV PEG-ASP. METHODS: A systematic literature search was conducted for all epidemiological studies that investigated IV and IM hypersensitivity rates for pediatric ALL...
August 31, 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27546298/differentiating-hypersensitivity-versus-infusion-related-reactions-in-pediatric-patients-receiving-intravenous-asparaginase-therapy-for-acute-lymphoblastic-leukemia
#6
Michael J Burke, Susan R Rheingold
Asparaginase is a key component of therapy for acute lymphoblastic leukemia (ALL). Traditionally, asparaginase was administered intramuscularly but is now commonly given intravenously. Although intravenous administration is less painful, it can be challenging to differentiate hypersensitivity versus infusion-related reactions. The ability to distinguish between asparaginase-mediated reactions is critical to ensure optimal asparaginase treatment. In this paper, we will review the differences in pharmacokinetics and toxicities, when asparaginase is administered intravenously versus intramuscularly in pediatric patients with ALL...
August 22, 2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27440950/l-asparaginase-in-the-treatment-of-patients-with-acute-lymphoblastic-leukemia
#7
REVIEW
Rachel A Egler, Sanjay P Ahuja, Yousif Matloub
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy that predominantly occurs in children between 2 and 10 years of age. L-asparaginase is an integral component of treatment for patients with ALL and since its introduction into pediatric treatment protocols in the 1960s, survival rates in children have progressively risen to nearly 90%. Outcomes for adolescent and young adult (AYA) patients, aged 15-39 years and diagnosed with ALL, have historically been less favorable. However, recent reports suggest substantially increased survival in AYA patients treated on pediatric-inspired protocols that include a greater cumulative dose of asparaginase...
April 2016: Journal of Pharmacology & Pharmacotherapeutics
https://www.readbyqxmd.com/read/27376478/allergic-like-reactions-to-asparaginase-atypical-allergies-without-asparaginase-inactivation
#8
Robin Q H Kloos, Rob Pieters, Gabriele Escherich, Inge M van der Sluis
BACKGROUND: Asparaginase is an important component of pediatric acute lymphoblastic leukemia (ALL) therapy. Unfortunately, this treatment is hampered by hypersensitivity reactions. In general, allergies - regardless of severity - cause complete inactivation of the drug. However, we report atypical allergic reactions without inactivation of asparaginase, here called allergic-like reactions. PROCEDURE: Patients with an allergic-like reaction, who were treated according to the Dutch Childhood Oncology Group ALL-11 or the CoALL 08-09 protocol, were described...
November 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/27299279/consensus-definitions-of-14-severe-acute-toxic-effects-for-childhood-lymphoblastic-leukaemia-treatment-a-delphi-consensus
#9
REVIEW
Kjeld Schmiegelow, Andishe Attarbaschi, Shlomit Barzilai, Gabriele Escherich, Thomas Leth Frandsen, Christina Halsey, Rachael Hough, Sima Jeha, Motohiro Kato, Der-Cherng Liang, Torben Stamm Mikkelsen, Anja Möricke, Riitta Niinimäki, Caroline Piette, Maria Caterina Putti, Elizabeth Raetz, Lewis B Silverman, Roderick Skinner, Ruta Tuckuviene, Inge van der Sluis, Ester Zapotocka
Although there are high survival rates for children with acute lymphoblastic leukaemia, their outcome is often counterbalanced by the burden of toxic effects. This is because reported frequencies vary widely across studies, partly because of diverse definitions of toxic effects. Using the Delphi method, 15 international childhood acute lymphoblastic leukaemia study groups assessed acute lymphoblastic leukaemia protocols to address toxic effects that were to be considered by the Ponte di Legno working group...
June 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27203165/-adverse-drug-reactions-in-pediatrics-experience-of-a-regional-pharmacovigilance-center
#10
Caroline Saint-Martin, Lukshe Kanagaratnam, Paul de Boissieu, Brahim Azzouz, Malak Abou Taam, Thierry Trenque
AIM: To describe the adverse drug reactions (ADR) and the drugs involved in pediatrics. METHODS: An observational study on all ADR notifications recorded in the French pharmacovigilance database by the Regional Pharmacovigilance Center of Champagne-Ardenne between 1 January 1985 and 31 December 2014 involving children from 0 to 17 years inclusive was performed. For all notifications, we studied the patient and the ADR characteristics. RESULTS: During the study period, 632 notifications were collected...
April 11, 2016: Thérapie
https://www.readbyqxmd.com/read/26928249/consensus-expert-recommendations-for-identification-and-management-of-asparaginase-hypersensitivity-and-silent-inactivation
#11
Inge M van der Sluis, Lynda M Vrooman, Rob Pieters, Andre Baruchel, Gabriele Escherich, Nicholas Goulden, Veerle Mondelaers, Jose Sanchez de Toledo, Carmelo Rizzari, Lewis B Silverman, James A Whitlock
L-asparaginase is an integral component of therapy for acute lymphoblastic leukemia. However, asparaginase-related complications, including the development of hypersensitivity reactions, can limit its use in individual patients. Of considerable concern in the setting of clinical allergy is the development of neutralizing antibodies and associated asparaginase inactivity. Also problematic in the use of asparaginase is the potential for the development of silent inactivation, with the formation of neutralizing antibodies and reduced asparaginase activity in the absence of a clinically evident allergic reaction...
March 2016: Haematologica
https://www.readbyqxmd.com/read/26834270/hypersensitivity-reactions-associated-with-l-asparaginase-administration-in-142-dogs-and-68-cats-with-lymphoid-malignancies-2007-2012
#12
Mary Kay Blake, Brittany J Carr, Glenna E Mauldin
Clinically significant hypersensitivity reactions (HSRs) to the chemotherapy drug L-asparaginase are reported in humans and dogs, but frequency in small animals is not well-defined. This study retrospectively evaluated the frequency of HSR to L-asparaginase given by IM injection to dogs and cats with lymphoid malignancies. The medical records of all dogs and cats treated with at least 1 dose of L-asparaginase chemotherapy over a 5-year period were reviewed. A total of 370 doses of L-asparaginase were administered to the dogs, with 88 of 142 dogs receiving multiple doses, and 6 dogs experiencing an HSR...
February 2016: Canadian Veterinary Journal. la Revue Vétérinaire Canadienne
https://www.readbyqxmd.com/read/26765930/asparaginase-erwinia-chrysanthemi-as-a-component-of-a-multi-agent-chemotherapeutic-regimen-for-the-treatment-of-patients-with-acute-lymphoblastic-leukemia-who-have-developed-hypersensitivity-to-e-coli-derived-asparaginase
#13
Lisa Figueiredo, Peter D Cole, Richard A Drachtman
Asparaginase has been a mainstay of therapy in the treatment of acute lymphoblastic leukemia since the 1970s. There are two major preparations available and FDA approved in the United States today, one derived from Escherichia coli and the other from Erwinia chrysanthemi. Erwinia asparaginase is antigenically distinct from and has a considerably shorter biological half-life than E coli asparaginase. Erwinia asparaginase has been used in cases of hypersensitivity to E. coli-derived asparaginases, which has been reported in up to 30% of patients...
March 2016: Expert Review of Hematology
https://www.readbyqxmd.com/read/26709607/cutaneous-t-cell-lymphoma-s%C3%A3-zary-syndrome-in-a-boxer
#14
Barbara C Rütgen, Irene Flickinger, Birgitt Wolfesberger, Barbara Litschauer, Andrea Fuchs-Baumgartinger, Sabine E Hammer, Armin Saalmüller, Ilse Schwendenwein
A 7-year-old male Boxer with a 3.5-year history of atopy and food hypersensitivity was presented with multiple poorly circumscribed nodules and maculae of the skin and tongue, and jaundiced mucosal membranes. Cytologic and histopathologic examination of the skin lesions revealed cutaneous epitheliotropic lymphoma. Cells were CD3(+) and CD8(+) in flow cytometry. The CBC showed a moderate leukocytosis with 16% atypical lymphocytes with irregularly cleaved nuclei. Flow cytometric phenotyping of peripheral blood showed an elevated proportion of the CD8(+) T-lymphocyte subpopulation, indicating a malignant population of T-cell origin, and the electropherogram of the PCR antigen receptor rearrangement produced a monoclonal peak for TCRγ...
March 2016: Veterinary Clinical Pathology
https://www.readbyqxmd.com/read/26558809/the-incidence-of-hypersensitivity-reactions-to-pegylated-asparaginase-in-children-with-acute-lymphoblastic-leukemia-a-city-wide-experience
#15
Muaz Alrazzak, Lynda K Beaupin, Peter Kinyoun, Matthew Barth
Asparaginase (ASNase) is an imperative component of pediatric acute lymphoblastic leukemia (ALL) therapy. Pegylating the ASNase extends its biological half-life in vivo and has become the only ASNase available in the United States for frontline therapy of ALL and lymphoblastic lymphoma. It is either infused intravenously (IV) or injected intramuscularly (IM), administrations of which are associated with hypersensitivity reaction ranging from localized skin reaction to severe anaphylaxis. A retrospective review of 96 medical records of pediatric ALL patients was performed...
January 2016: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/26457809/subgroups-of-paediatric-acute-lymphoblastic-leukaemia-might-differ-significantly-in-genetic-predisposition-to-asparaginase-hypersensitivity
#16
Nóra Kutszegi, Ágnes F Semsei, András Gézsi, Judit C Sági, Viktória Nagy, Katalin Csordás, Zsuzsanna Jakab, Orsolya Lautner-Csorba, Krisztina Míta Gábor, Gábor T Kovács, Dániel J Erdélyi, Csaba Szalai
L-asparaginase (ASP) is a key element in the treatment of paediatric acute lymphoblastic leukaemia (ALL). However, hypersensitivity reactions (HSRs) to ASP are major challenges in paediatric patients. Our aim was to investigate genetic variants that may influence the risk to Escherichia coli-derived ASP hypersensitivity. Sample and clinical data collection was carried out from 576 paediatric ALL patients who were treated according to protocols from the Berlin-Frankfurt-Münster Study Group. A total of 20 single nucleotide polymorphisms (SNPs) in GRIA1 and GALNT10 genes were genotyped...
2015: PloS One
https://www.readbyqxmd.com/read/26457414/asparaginase-associated-toxicity-in-children-with-acute-lymphoblastic-leukemia
#17
Nobuko Hijiya, Inge M van der Sluis
Asparaginase is an integral component of multiagent chemotherapy regimens for the treatment of children with acute lymphoblastic leukemia. Positive outcomes are seen in patients who are able to complete their entire prescribed course of asparaginase therapy. Toxicities associated with asparaginase use include hypersensitivity (clinical and subclinical), pancreatitis, thrombosis, encephalopathy, and liver dysfunction. Depending on the nature and severity of the toxicity, asparaginase therapy may be altered or discontinued in some patients...
2016: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/26376459/activity-and-toxicity-of-intravenous-erwinia-asparaginase-following-allergy-to-e-coli-derived-asparaginase-in-children-and-adolescents-with-acute-lymphoblastic-leukemia
#18
MULTICENTER STUDY
Lynda M Vrooman, Ivan I Kirov, ZoAnn E Dreyer, Michael Kelly, Nobuko Hijiya, Patrick Brown, Richard A Drachtman, Yoav H Messinger, A Kim Ritchey, Gregory A Hale, Kelly Maloney, Yuan Lu, Paul V Plourde, Lewis B Silverman
BACKGROUND: Erwinia asparaginase is antigenically distinct from E.coli-derived asparaginase and may be used after E.coli-derived asparaginase hypersensitivity. In a single-arm, multicenter study, we evaluated nadir serum asparaginase activity (NSAA) and toxicity with intravenously administered asparaginase Erwinia chrysanthemi (IV-Erwinia) in children and adolescents with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma with hypersensitivity to E.coli-derived asparaginase...
February 2016: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/25987655/genome-wide-analysis-links-nfatc2-with-asparaginase-hypersensitivity
#19
Christian A Fernandez, Colton Smith, Wenjian Yang, Charles G Mullighan, Chunxu Qu, Eric Larsen, W Paul Bowman, Chengcheng Liu, Laura B Ramsey, Tamara Chang, Seth E Karol, Mignon L Loh, Elizabeth A Raetz, Naomi J Winick, Stephen P Hunger, William L Carroll, Sima Jeha, Ching-Hon Pui, William E Evans, Meenakshi Devidas, Mary V Relling
Asparaginase is used to treat acute lymphoblastic leukemia (ALL); however, hypersensitivity reactions can lead to suboptimal asparaginase exposure. Our objective was to use a genome-wide approach to identify loci associated with asparaginase hypersensitivity in children with ALL enrolled on St. Jude Children's Research Hospital (SJCRH) protocols Total XIIIA (n = 154), Total XV (n = 498), and Total XVI (n = 271), or Children's Oncology Group protocols POG 9906 (n = 222) and AALL0232 (n = 2163). Germline DNA was genotyped using the Affymetrix 500K, Affymetrix 6...
July 2, 2015: Blood
https://www.readbyqxmd.com/read/25865363/a-critical-review-on-properties-and-applications-of-microbial-l-asparaginases
#20
Prajna Rao Krishnapura, Prasanna D Belur, Sandeep Subramanya
l-Asparaginase is one of the main drugs used in the treatment of acute lymphoblastic leukemia (ALL), a commonly diagnosed pediatric cancer. Although several microorganisms are found to produce l-asparaginase, only the purified enzymes from E. coli and Erwinia chrysanthemi are employed in the clinical and therapeutic applications in humans. However, their therapeutic response seldom occurs without some evidence of hypersensitivity and other toxic side effects. l-Asparaginase is also of prospective use in food industry to reduce the formation of acrylamide in fried, roasted or baked food products...
September 2016: Critical Reviews in Microbiology
keyword
keyword
61753
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"